(Q33186211)

23 July 2017

title

Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study (English)

1 reference

multicenter clinical trial

23 July 2017

main subject

0 references

author name string

Daniel E Casey

1

1 reference

23 July 2017

William H Carson

2

1 reference

23 July 2017

Anutosh R Saha

3

1 reference

23 July 2017

Amy Liebeskind

4

1 reference

23 July 2017

Mirza W Ali

5

1 reference

23 July 2017

Darlene Jody

6

1 reference

23 July 2017

Gary G Ingenito

7

1 reference

23 July 2017

Aripiprazole Study Group

8

1 reference

23 July 2017

publication date

28 February 2003

1 reference

23 July 2017

number of pages

9

1 reference

inferred from page(s)

published in

Psychopharmacology

1 reference

23 July 2017

volume

166

1 reference

23 July 2017

issue

4

1 reference

23 July 2017

page(s)

391-399

1 reference

https://scigraph.springernature.com/pub.10.1007/s00213-002-1344-3

23 July 2017

exact match

0 references

cites work

A rating scale for drug-induced akathisia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-002-1344-3

The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-002-1344-3

Antipsychotic medication: effects on regulation of glucose and lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-002-1344-3

Buspirone: an update on a unique anxiolytic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-002-1344-3

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-002-1344-3

Schizophrenia with good and poor outcome. I: Early clinical features, response to neuroleptics and signs of organic dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-002-1344-3

Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-002-1344-3

Effects of Nefazodone on Body Weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-002-1344-3

Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.

21 January 2018

1 reference

12 December 2020

Review of atypical antipsychotics and weight gain.

1 reference

12 December 2020

The relationship of pharmacology to side effects

1 reference

12 December 2020

Mechanisms of antipsychotic-induced weight gain

1 reference

12 December 2020

Important issues in the drug treatment of schizophrenia

1 reference

12 December 2020

Switching approach in the management of schizophrenia patients

1 reference

12 December 2020

Treatment of neuroleptic-resistant schizophrenic relapse.

1 reference

12 December 2020

Switching clozapine responders to olanzapine.

1 reference

12 December 2020

7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.

1 reference

12 December 2020

Conventional versus novel antipsychotics: changing concepts and clinical implications

1 reference

12 December 2020

Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.

1 reference

12 December 2020

The clinical implications of weight gain in schizophrenia.

1 reference

12 December 2020

Treatment of schizophrenia

1 reference

12 December 2020

Use of buspirone in the treatment of schizophrenia

1 reference

12 December 2020

Effects of atypical antipsychotics on weight and serum lipid levels

1 reference

12 December 2020

Compliance with antipsychotic drug treatment: influence of side effects.

1 reference

12 December 2020

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

1 reference

12 December 2020

Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.

1 reference

12 December 2020

Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs

1 reference

12 December 2020

Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland

1 reference

12 December 2020

Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics

1 reference

12 December 2020

10.1007/S00213-002-1344-3

Identifiers

DOI

1 reference

Dimensions Publication ID

23 July 2017

1053395398

0 references

1 reference